Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.

Stay updated with Wall Street's weekly highlights: key inflation data, CoreWeave IPO, and earnings reports. Insights on ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.